Rani Therapeutics Holdings, Inc. (RANI)
0.854
+0.01
(+1.67%)
USD |
NASDAQ |
Aug 31, 15:07
Rani Therapeutics Holdings EPS Diluted (Quarterly) : -0.0395 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0395 |
| March 31, 2026 | -0.0391 |
| December 31, 2025 | -0.0701 |
| September 30, 2025 | -0.1165 |
| June 30, 2025 | -0.1831 |
| March 31, 2025 | -0.2172 |
| December 31, 2024 | -0.2739 |
| September 30, 2024 | -0.2352 |
| June 30, 2024 | -0.2585 |
| March 31, 2024 | -0.2874 |
| December 31, 2023 | -0.2743 |
| September 30, 2023 | -0.3599 |
| June 30, 2023 | -0.367 |
| Date | Value |
|---|---|
| March 31, 2023 | -0.3317 |
| December 31, 2022 | -0.3527 |
| September 30, 2022 | -0.3251 |
| June 30, 2022 | -0.3128 |
| March 31, 2022 | -0.2907 |
| December 31, 2021 | -0.2632 |
| September 30, 2021 | -0.1594 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | -0.1377 |
| March 31, 2020 | -0.271 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -0.2295 |
| CNBX Pharmaceuticals, Inc. | -0.0001 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 2.578 |
| Fulcrum Therapeutics, Inc. | -0.3433 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.421M |
| Revenue (Quarterly) | 1.708M |
| Total Expenses (Quarterly) | 9.099M |
| Enterprise Value | 53.21M |
| Gross Profit Margin (Quarterly) | 88.29% |
| Profit Margin (Quarterly) | -493.0% |
| Earnings Yield | -31.05% |
| Normalized Earnings Yield | -30.73 |